Artis BioSolutions Emerges from Stealth, Announces Acquisition of Landmark Bio
Summary
SAN DIEGO--(BUSINESS WIRE)--Artis BioSolutions, a company founded to streamline the discovery, development and production of genetic medicines, today announced its launch, alongside its acquisition of Landmark Bio. “Landmark Bio was born from a bold vision shared by our founding partners – to remove barriers in the manufacturing of advanced therapies and accelerate the development of life-changing medicines. Artis BioSolutions is led by CEO Brian Neel and CSO Mike Houston, two leaders with deep expertise in deploying best-in-class systems and technologies in the CDMO and broader therapeutics space. “Brian and Mike are exceptional leaders with deep domain expertise and experience hyper-scaling advanced therapy tools and services companies,” said Andrew Adams, Co-Founder and Managing Partner at Oak HC/FT. Designed to support breakthrough treatments, we offer innovative technology, deep expertise, and a client-focused approach to streamline processes, improve efficiency, and scale across various therapeutic areas.